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Highlights 
 Gout is a disease of urate crystal deposition that manifests primarily as 
inflammatory arthritis. 
 Gout is not a disease that is present only during gouty flares: it is a chronic 
urate crystal deposition disease with flares being a symptomatic 
manifestation. 
 Treating gout requires lowering serum urate levels to a predefined target to 
induce remission. 
 Gout is associated with multiple co-morbidities that often complicate 
management and these co-morbidities should be identified and managed 
appropriately as part of the care of a patient with gout. 
 The way allopurinol is initiated has changed, with lower doses used initially 
and slow uptitration, to improve safety and reduce associated flares. 
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Gout is an increasingly common chronic disorder of urate crystal deposition that 
manifests as flares of acute inflammatory arthritis. Hyperuricaemia is a prerequisite 
and a fifth of both men and woman are hyperuricaemic. The prevalence of gout is 
much lower than the prevalence of hyperuricaemia for reasons that are not currently 
clear. Gout is more common in men than women prior to menopause due to the 
uricosuric effects of oestrogen, but after menopause the incidence of gout rises 
substantially in women. Co-morbidities are an important issue in gout, with 
cardiovascular disease, diabetes mellitus, obesity and chronic kidney disease all 
common in patients with gout. Environmental factors like diet affect the incidence of 
gout but there is little evidence to support an emphasis on diet in treating established 
gout. The diagnosis of gout is often made without the use of joint aspiration and 
validated diagnostic rules are available for both primary and secondary care as well 
as classification criteria for research use. The overarching principle of the 
management of gout with pharmacotherapy is the need to reduce serum urate levels 
to below a target of 0.30mmol/L or 0.36mmol/L depending on whether it is 
tophaceous or non-tophaceous respectively. The use of allopurinol has been 
researched extensively and newer strategies for safer effective dosing are now 
recommended. Newer agents have been introduced for the treatment of gout, 
including febuxostat and lesinurad. A number of important questions in the field are 
under current investigation. 
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1.0 Introduction 
Gout is a chronic urate crystal deposition disease. As patients accumulate urate 
crystals over time their risk of clinically manifest gout increases. Gout is not a 
disease that is only present during gouty flares, it is a chronic urate crystal deposition 
disease with flares being a symptomatic manifestation. This distinction is important 
as it justifies the effort to lower serum urate (SU) in patients to prevent symptoms 
and joint damage.  
 
The challenges in gout care centre on diagnosis and introduction of treatment as well 
as maintaining adherence to urate lowering therapy (ULT). This review aims to both 
highlight important points in gout and provide an update since the last review of this 
topic in Maturitas (1). 
 
Major papers in the field since the last published manuscript were reviewed and 
included if they were felt to be important to the understanding of gout or its 
management. Papers that marked significant changes in understanding or 
management from anytime were included if they sought to change long held beliefs 
or practice that takes an extended time to disseminate throughout the medical and 
scientific community. Specifically, Medline [via Web of Science] was searched from 
2014 - 2018 with the topic term ‘gout’ (15,198 results) and restricted by ‘highly 
sighted’ and ‘hot papers’ (73 results) which were then examined individually, initially 
by title and abstract review, then by full text review.      
 
2.0 Aetiology 
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While gout has been considered by some in the past as a disease of excess and 
over-indulgence this view is increasingly being replaced by a more nuanced view (2). 
When gout is viewed as a chronic disease of urate crystal deposition then its cause 
can be related back to an imbalance between urate intake/production and excretion 
leading to urate accumulation and crystallisation in tissues. This creates the 
environment for innate immune system attack and the resultant acute inflammatory 
state and clinical manifestations. 
 
2.1 Genetics 
The vast majority of gout patients are under excreters of urinary urate compared to 
the normal population. Patients with gout have higher tubular reabsorption of urate 
(3, 4). This elevated reabsorption level is driven by genetic variation in urate 
transporters (5). The most significant genetic associations are SLC2A9 (GLUT9) and 
SLC22A12 (URAT1) with a large number of other genes, including numerous 
transporters, making smaller contributions. More recently discovered is the 
contribution of decreased function of the ABCG2 transporter in the gut contributing to 
hyperuricaemia (6). Genetic variation makes a substantial contribution to the 
variation seen in the prevalence of gout across different ethnic groups (7, 8). 
 
Recent developments in gout genetics include the discovery of an association 
between reduced mitochondrial genetic copy number and gout (9). The nature of the 
link is currently unclear but may relate to innate immune system functioning. Multiple 
groups have also identified rare variants in genes encoding transporters such as 
ABCG2, SLE22A1 and a gene encoding a member of the aldehyde dehydrogenase 
superfamily ALDH16A1 associated with gout (10-12). The association with variants 
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in ALDH16A1 is of note because the ALDH16A1 protein may interact with 
hypoxanthine-guanine phosphoribosyltransferase (HPRT1), a urate processing 
protein (13). HPRT1 deficiency causes Lesch-Nyhan Syndrome and urate 
accumulation (14). There has been a recent large Japanese genome wide 
association study (GWAS) which investigated genetic causes of hyperuricaemia. 
This study, along with others, helps define the non-European genetic associations 
with SU which are not as well investigated as European associations (15). The 
global gout genetics consortium has also planned a very large gout GWAS which will 
have power to detect a significant number of additional genetic associations. These 
recent discoveries are starting to build a more complex picture of the significant 
contribution that genetics makes to gout (16). 
 
2.2 Environment Factors  
The primary sources of urate are (1) dietary purines and foodstuffs that are 
converted into urate (eg. fructose), and (2) metabolism, from purine degradation (eg. 
cellular repair and replacement). Large epidemiological studies have demonstrated 
that intake of alcohol, sugar sweetened beverages and fructose, organ meat and 
seafood contribute to hyperuricaemia (17-19). However, it is worth noting that there 
is a lack of evidence from education and intervention trials that dietary limitation of 
these sources of urate makes a clinically meaningful impact on the management of 
established gout (20, 21). Patients may be able to achieve small reductions in SU 
with diet alone but these SU changes have not been shown to lead to sustained 
reductions in the frequency of gout flares. One illustrative trial provided dietary 
education twice to the intervention group and usual care to the control group and 
while there was improvement in knowledge and change in diet there was no change 
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is SU (20). A recent study examining the relative contributions of diet and genetics to 
SU levels in 17,000 participants found that consumption of 16 food items were 
associated with SU levels(2). Variation in consumption of these food items explained 
3.3% of the SU variance whereas genetics explained 24% of SU variance. This 
combined simultaneous examination demonstrates how little diet contributes to SU 
variation. 
 
Weight loss does lower SU substantially though (22). As an illustrative example of 
how weight loss can lower SU, a bariatric surgery study noted SU levels greater than 
0.41mmol/L present in 83% of those with gout prior to surgery and 33% one year 
after operation (23). This is supported by the Mendelian randomisation evidence that 
fat mass directly increases SU (24, 25). These changes in SU are likely to translate 
into meaningful differences in clinical gout management (26). 
 
There is extensive data about the impact of lifestyle and diet factors on the incidence 
of gout. A Health Professionals Follow-Up study cohort analysis over 26 years found 
that a diet with concordance with the Dietary Approaches to stop Hypertension 
(DASH) led to lower incident gout (27). This diet has higher fruits, nuts, legumes and 
vegetables and low-fat dairy products, and whole grains, and low intake of sodium, 
sweetened beverages, and red and processed meats did lead to lower incident gout. 
Bariatric surgery also makes a clinically meaningful difference to gout incidence with 
a large Swedish study of 1,982 obese patients and 1,999 obese controls finding an 
adjusted hazard ratio of 0.60 for gout incidence after surgery (28).  
 
2.3 The transition from hyperuricaemia to gout 
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Only a proportion of patients with hyperuricaemia develop gout. Using the 2007 – 
2008 United States National Health and Nutrition Examination Survey Choi and 
colleagues determined that the prevalence of gout was 5.9% and 2.0% in men and 
women respectively. However, the prevalence of hyperuricaemia was 21.2% and 
21.6% in men and women respectively (29). Therefore only 28% of men and 9% of 
women in this cohort who are hyperuricaemic also had gout.  
 
It is currently not clear what all the influences are that make a hyperuricaemic person 
develop gout, but the level of SU and the volume of urate crystals is potentially 
important. There is a strong relationship between level of SU and gout (30, 31). 
Imaging studies have demonstrated that the frequency and volume of urate crystals 
increases from the asymptomatic hyperuricaemic state to the clinically manifest gout 
state (32). Therefore, one explanation for the observed discrepancy between 
hyperuricaemia and gout would be that people who are hyperuricaemic are in the 
process of accumulating a crystal load that reaches a certain threshold to trigger 
gout. However, the discrepancy between those with raised SU and those with raised 
SU and gout is very large and variation in the functioning of the innate immune 
response to crystals may also potentially play a role. Supporting this theory is the 
finding from a study of weight loss after bariatric surgery where 20 participants went 
from a mean of 123 kg to a mean of 98kg. Significant reductions in white cell 
responses to monosodium urate crystals in respect to interleukin (IL)-1β, IL-8 and IL-
6 were observed (33). This finding suggests that factors outside of the mere 
presence or volume of urate crystals play a role. In addition, two studies have found 
association between a critical component of the innate immune system and gout. 
The Toll-like receptor 4 variant rs2149356 has been found to be associated with 
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gout. However, the association was not found in all cohorts studied and needs 
further verification (34, 35). Finally, IgM antibodies that can bind monosodium urate 
crystals have been identified (36). These antibodies are able to promote urate 
crystallisation, so there is also potential involvement of the humoral immune system 
in the pathogenesis of gout. 
 
Clinical studies of molecules that inhibit the innate immune response, for example 
canakinumab - a monoclonal IL-1 inhibitor, have already shown efficacy for treating 
and preventing gout flares (37). If further progress can be made in identifying the 
factors that turn a hyperuricaemic person into a patient with gout then this can 
provide fruitful opportunities to intervene to prevent this transition. The asymptomatic 
hyperuriciaemic person, with or without crystal deposition, has been included in a 
proposed staging system of gout, in part to “provide a rational basis for testing the 
potential role for screening of asymptomatic disease” (38). 
 
3.0 Epidemiology 
There is a steady increase in the prevalence of gout as men age with rates in elderly 
males well exceeding 10% in many cohorts (39, 40). Ethnicity also strongly 
influences gout prevalence with substantially higher prevalence rates of gout in 
groups like the New Zealand Maori, Pacific Islanders and Taiwanese. For example, 
in elderly New Zealand Maori the prevalence rate in males exceeds 40% (7). Gout 
prevalence in woman is much lower until the menopause due to oestrogen causing 
urate loss in the urine (41). It then rises substantially compared to pre-menopausal 
women but does not become as common as in elderly men, for example, the 
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prevalence in 80 year old New Zealand European women is around 7%, whereas in 
men it is around 17% (7). 
 
4.0 Diagnosis 
The majority of gout is diagnosed and managed in primary care. In this setting the 
diagnosis of gout is usually made on clinical grounds, considering the age, co-
morbidities, symptoms, clinical signs and laboratory results. However, the gold 
standard of diagnosis is joint aspiration demonstrating monosodium urate crystals on 
microscopy. Due to practical issues the majority of patients do not have joint 
aspiration. This is often due to lack of skills, lack of a polarising light microscope or 
lack of time.  
 
While clinical characteristics can be very helpful, they cannot be relied on 
exclusively. A study from the Netherlands examined 159 primary care patients 
presenting with acute 1st metatarsophalangeal (MTP) joint arthritis. It found a GP 
diagnosis of gout had a 0.99 sensitivity, 0.07 specificity, positive predictive value of 
0.79 and negative predictive value of 0.75 (42). After 6 years of follow-up it was 
found that 77% had gout, 8% had another rheumatic disease and 15% had a 
transient unspecified monoarthritis. So 1st MTP arthritis is very likely to be gout, in 
around ¾ but in ¼ it is not. A diagnostic rule for the diagnosis of gout without an 
aspirate has been constructed and validated in both primary and secondary care, 
shown in Table 1 (43, 44). Classification criteria have also been constructed for 
research purposes, shown in Table 2. However, it is important to note these are 
designed for research use and not validated for clinical diagnostic use (45). 
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5.0 Co-morbidities 
The co-morbidities of hypertension, chronic kidney disease (CKD), obesity and 
diabetes mellitus are common in gout patients (46, 47). CKD causes elevated SU. 
Many studies have demonstrated an association between gout and hypertension, 
diabetes and cardiovascular disease but there remains no convincing evidence that 
the presence of gout or raised SU contributes causally to these problems (48). Some 
animal evidence has found causal relationships between raised SU and disease, for 
example hypertension, but there remains a lack of consistent animal or human data 
to support this (49). There have also been interventional studies in humans with ULT 
with positive results, but the studies have been small and xanthine oxidase inhibitors 
also reduce systemic oxidative stress, so the exact mechanism by which the 
observed effects are occurring is unclear (50-52). Oxidative stress plays an 
important role in vascular endothelial dysfunction and reducing it through inhibiting 
the xanthine oxidase pathway has the potential to improve cardiovascular outcomes 
(53). In concert with this allopurinol initiation has been found to reduce death in a 
propensity score matched cohort study from the United Kingdom (54). Regardless of 
the causal nature of SU in co-morbidities the presence of them does mean that when 
gout is diagnosed then co-morbidities need to be considered and managed 
appropriately. 
 
One of the major co-morbidities is CKD which presents challenges in the use of 
drugs to treat and prevent acute flares such as non-steroidal anti-inflammatories. 
CKD does also necessitate the slower up-titration of the urate lowering drug 
allopurinol. The Hande proposal to limit final allopurinol dose based on renal function 
has been replaced by the recommendation to start at an appropriate low dose and 
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cautiously up titrate the allopurinol dose until SU target has been met, see Table 3 
(55, 56). 
 
There have been recent proposals to group patients with gout based on their co-
morbidities. Richette and colleagues used cluster analysis to identify five distinct 
clusters in a cohort of 2,763 French patients with gout (57). Cluster 1 had gout alone, 
cluster 2 had obesity, dyslipidaemia and hypertension, cluster 3 has 75% diabetes 
and dyslipidaemia, cluster 4 had pure dyslipidaemia and the cluster 5 had all those 
with heart disease, heart failure and renal failure. Roddy and colleagues have also 
identified co-morbidity clusters in gout patients (58). While these clusters have been 
observed, it remains to be seen how they relate to either pathophysiological 
processes or our approach to the clinical management of gout.     
 
6.0 Management 
 
6.1 Treatment principles 
Guidelines suggest the commencement of urate lowering therapy when people with 
gout have more than one flare per year, see Table 4 (59). When treating gout with 
ULT it is important that the patient is aware that you are trying to deplete their body 
of urate crystal deposition. As such a long term, lifelong approach is required.  
 
6.2 Patient Education 
It is increasingly being recognised that patient education is an important part of gout 
management. If patients understand that gout is a chronic disease that requires long 
term therapy, then this may help with understanding the importance of adherence. A 
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British research group has shown that when education is used as part of a package 
of care then there is a high rate of reaching SU targets (92 - 95% at target at 12 
months, and 95% at 24 months)(60, 61). There are some critical points about gout 
that it is important that patients understand and often education materials don’t cover 
all of the important points (62). The first is that it is a chronic disease with flares, and 
not an episodic disease with attacks, the second is that it is often progressive, 
without treatment patients who experience a flare have a 63% chance of recurrence, 
in a mean of 3.5 years (63). So once started on ULT, the expectation is that this 
should continue lifelong to ensure gout flares don’t recur. 
 
6.3 Initiating urate lowering therapy 
ULT is the core of effective gout management. The most common and 
recommended first line ULT is allopurinol (59, 64). The indications for initiating ULT 
are shown in Table 4. Historically it has been taught that ULT should not be 
commenced during an acute flare due to a perceived risk that the gout flare would be 
worsened. Two clinical trials including a total of 88 patients have now demonstrated 
that there is no difference in pain visual analogue scale outcome between anti-
inflammatory treatment and combined anti-inflammatory and ULT treatment, see 
Figure 1 from the Taylor clinical trial  (65, 66). This approach is also supported in the 
American College of Rheumatology guidelines (59). There is also evidence that 
patients who have ULT initiated during an acute gout flare are significantly more 
likely to reach their target serum urate earlier (67).  
 
6.4 Treating serum urate to target 
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The effective treatment of gout revolves around the treatment of SU to target. The 
European League Against Rheumatism (EULAR) and the American College of 
Rheumatology’s recommended SU target is less than 0.36mmol/L for non-
tophaceous gout and less than 0.30mmol/L for tophaceous gout (59, 68). The British 
Society for rheumatology recommends a SU target of 0.30mmol/L for all patients 
with gout (69). These SU targets are, although different, all below the crystallisation 
point of urate at body temperature. The rationale for lower serum urate targets in 
those with tophaceous disease is that they have a higher crystal burden and the 
lower SU is the faster crystals will dissolve (70). Quality of care studies have shown 
that the minority of patients with gout are treated to target and therefore are unlikely 
to be free of symptoms (39). 
 
6.4.1 Allopurinol 
Allopurinol continues to be core therapy for urate lowering in gout. To reduce the risk 
of allopurinol hypersensitivity syndrome (AHS) it should be started at no more than 
100mg per day and increased by 100mg every 2-5 weeks in those with renal function 
greater than 30mL/min. In those with renal function less than 30mL/min it is 
recommended to start at 50mg per day and increase slowly. Some authors 
recommend that a starting dose less than 100mg also be used in those in the 30 - 
60mL/min renal function range (55). In those at higher risk of AHS then testing for 
the presence of the HLA-B*5801 allele is recommended (59). Patients with gout from 
Asian countries have a higher population prevalence of this allele compared to those 
of European descent, and those with renal impairment are also at increased risk 
(37). Universal screening for HLA-B*5801 is not recommended due to the low 
prevalence of the allele in European populations. 
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 The treatment strategy of slowly up-titration of allopurinol to reach SUA target has 
been demonstrated to be safe and effective in a study from New Zealand (71-73). 
Although it needs to be noted that the prevalence AHS preclude definitive safety 
conclusions from clinical trials. The recommendations to take this approach are 
informed by a large case-control study that concluded that the relationship between 
renal function and allopurinol hypersensitivity was based on high starting doses of 
allopurinol, not on high maintenance doses (55). The mechanism relates to immune 
system tolerance to allopurinol (74). 
 
6.4.2 Febuxostat 
The introduction of febuxostat as a xanthine oxidase inhibitor for ULT was a 
significant step in gout therapeutics (75). At the time of registration it was noted that 
there were potentially concerning cardiovascular safety signals in the registration 
trials. As an example, in the APEX trial there were 11 cardiovascular events in the 
670 febuxostat patients, 1 in the 268 allopurinol patients and 1 in the 134 placebo 
patients (76). Mandated safety trials were completed, and the US based trial has 
been published (CARES) with the European trial still pending (FAST, febuxostat 
versus allopurinol streamlined trial) and an additional Japanese trial in asymptomatic 
hyperuricaemia also ongoing ((FREED: febuxostat for cerebral and cardio-
renovascular events prevention study) (64, 77, 78). The CARES study randomized 
6,190 patients to allopurinol or febuxostat for a median of 32 months (79). The 
primary composite cardiovascular endpoint did not show a significant difference. 
However, death from any cause was increased in the febuxostat group with a hazard 
ratio of 1.22 (95% confidence interval (CI) 1.01 – 1.47) and there was also an 
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increase in cardiovascular death with a hazard ration of 1.34 (95% CI 1.03 – 1.73). 
The design of the trial does not allow conclusions relating to the absolute effect of 
febuxostat on risk of death, only the relative effect compared to allopurinol. The trial 
also had a high drop-out rate which may have introduced bias. The implications and 
possible explanations are discussed in this excellent review (64). These data now 
mean that consideration of this increase in death needs to be discussed with patients 
taking or contemplating taking ULT. As a result of these data it has now been 
recommended that febuxostat should not be used as first line ULT (64). 
 
6.4.3 Probenecid 
Probenecid is a uricosuric drug that promotes urate wasting in the urine. It should be 
avoided in those with kidney stones, or those with elevated urinary uric acid, 
namely fractional excretion of uric acid > 6% or urinary uric acid excretion > 700 
mg/day/1.73 m2 (80). The procedure for measuring spot fractional excretion of urate 
simply requires simultaneous collection of urine and plasma creatinine and urate, 
and then taking the product of the urinary creatinine and the plasma urate and 
dividing by the product of the plasma creatinine and the urinary urate (81). 
Probenecid is often used second line or as add on therapy to a xanthine oxidase 
inhibitor for ULT. It has historically been felt to not be effective in those with reduced 
renal function but recent case series data has suggested it is as effective in those 
with GFR < 50ml/min as it is in those with a GFR > 50mL/min (82). 
 
6.4.4 Lesinurad 
Lesinurad is a newly launched uricosuric agent. It is available in a 200mg daily dose. 
The dose of 400mg was also extensively tested in clinical trials but primarily due to 
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renal adverse events this was not registered in the United States (83). It is 
recommended that it be taken with a xanthine oxidase inhibitor to reduce the risk of 
renal adverse events. It is available in a combination tablet with 200mg lesinurad and 
300mg allopurinol. It is currently unclear where it will sit in treatment algorithms. 
However, based on currently available information, in contrast to probenecid, 
lesinurad has fewer drug-drug interactions, but this position may change as it is used 
more widely in clinical practice.     
 
6.5 Prophylaxis of acute flares while serum urate is being lowered 
One of the challenges in managing gout is the successful introduction of urate 
lowering therapy. It is a well-recognised phenomenon that the introduction of SU 
lowering agents can cause gout to flare. This is thought to be due to ‘mobilisation’ of 
crystals, although the exact mechanism is not understood. All major guidelines 
recommend flare prophylaxis with colchicine or non-steroidal anti-inflammatory 
agents (68, 69, 84). Flares can extend for an extended period of time after SU target 
has been reached. Patients in the trial of nurse-led therapy had a mean of 1.5 gout 
flares even though 95% had been at or below their SU target for a year (61). 
 
6.6 Asymptomatic hyperuricaemia  
There is currently no indication for the treatment of asymptomatic hyperuricaemia 
and it is not recommended by any management guideline. By definition the patient 
does not have any symptoms of gout and the only abnormality is a raised SU on 
pathology testing. This does not represent a disease and there is no evidence that 
treatment in this group is either effective or safe. Although the level of SU is 
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correlated to the risk of developing gout, only around 20 – 25% of people with raised 
SU develop gout (29).  
 
6.7 Patient Follow-Up 
Once a patient with gout has reached their serum urate target it is not uncommon for 
them to continue to experience flares for extended periods. In the FOCUS study of 
febuxostat it was over 4 years before patients completely stopped experiencing 
flares (85). Other groups have found similar results (61, 63). The American College 
of Rheumatology has recommended that patients have a SU test every 6 months 
after target SU is achieved (59). This has been shown to be a cost-effective 
intervention based on assumptions regarding increases in medication adherence, 
and reductions in the cost of flare treatment (86). 
 
7.0 Summary 
There has been substantial progress in the strategies for the clinical management of 
gout, including a safer strategy for commencing allopurinol, a greater emphasis on 
prophylaxis of acute gout flares whilst commencing ULT and a strong focus on 
treating SU to target for effective gout management. This all demonstrates significant 
progress in managing this long neglected disease which has a huge impact on 
patients. There remains a number of important unanswered questions in the field, 
including what the optimal SUA target is and the safety of lowering SU very low (87-
89). There are also proposals for different approaches to management, including the 
‘oncology’ approach of induction therapy with rapid crystal depletion with intravenous 
uricase therapy and then maintenance therapy with oral agents. It remains to be 
seen whether these proposed approaches prove safe and effective.   
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Table 1: Janssens/Kienhorst validated diagnostic rule for diagnosis of gout (1, 2) 
 
Parameter Score  
Male Sex 2 
Previous patient-reported arthritis attack 2 
Onset within 1 day 0.5 
Joint redness 1 
MTPJ1 involvement 2.5 
Hypertension or ≥1 cardiovascular diseases* 1.5 
Serum uric acid level > 5.88 mg/dL / 0.35mmol/L 3.5 
 
Score ≤ 4 = Very low likelihood of gout (95 - 97.2% non-gout); Score > 4 & < 8 = Diagnosis 
uncertain, obtain joint aspirate; Score ≥ 8 = High likelihood of gout (80 – 87% gout)  
 
MTPJ1, first metatarsophalangeal joint 
*Angina pectoris, myocardial infarction, heart failure, cerebrovascular accident, transient 
ischemic attack, or peripheral vascular disease 
 
1. Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A 
diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch 
Intern Med. 2010;170(13):1120-6. 
2. Kienhorst LB, Janssens HJ, Fransen J, Janssen M. The validation of a diagnostic rule 
for gout without joint fluid analysis: a prospective study. Rheumatology (Oxford). 
2015;54(4):609-14. 
 
Table 2: ACR/EULAR 2015 Gout Classification Criteria (1) 
 
Criteria Category Score 
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Pattern of joint/bursa involvement 
during symptomatic episode(s) ever 
Ankle or midfoot (as part of 
monoarticular or oligoarticular episode 
without involvement of the first 
metatarsophalangeal joint) 
1 
 Involvement of the first 
metatarsophalangeal joint (as part of 
monoarticular or oligoarticular episode) 
2 
Characteristics of symptomatic 
episode(s) ever  
- Erythema overlying affected joint 
(patient- reported or physician-
observed) 
One characteristic 1 
- Can’t bear touch or pressure to 
affected joint  
Two characteristics 2 
- Great difficulty with walking or 
inability to use affected joint 
Three characteristics 3 
Time course of episode(s) ever: 
Presence (ever) of ≥2, irrespective of 
anti-inflammatory treatment: 
-Time to maximal pain <24 hours  
-Resolution of symptoms in ≤14 days  
-Complete resolution (to baseline level) 
between symptomatic episodes 
One typical episode 1 
 Recurrent typical episodes 2 
Clinical evidence of tophus - Draining 
or chalk-like subcutaneous nodule 
under transparent skin, often with 
overlying vascularity, located in typical 
locations: joints, ears, olecranon 
bursae, finger pads, tendons (e.g., 
Achilles) 
 
Present 4 
Serum urate: Measured by uricase 
method. 
Ideally should be scored at a time 
when the patient was 
not receiving urate-lowering treatment 
and it was 4 weeks from the start of an 
episode (i.e., during intercritical 
period); if practicable, retest under 
those conditions. 
The highest value irrespective of timing 
should be scored 
 
<4 mg/dl (<0.24 mmol/litre) 
 
-4 
 6–≤8 mg/dl (0.36–≤0.48 mmol/litre) 
 
2 
 8–≤10 mg/dl (0.48–≤0.60 mmol/litre) 3 
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  >10 mg/dl (0.60 mmol/litre) 
 
4 
Synovial fluid analysis of a 
symptomatic (ever) joint or bursa 
(should be assessed by a trained 
observer) 
 
MSU negative -2 
Imaging evidence of urate deposition 
in symptomatic (ever) joint or bursa: 
ultrasound evidence of double-contour 
sign or DECT demonstrating urate 
deposition 
 
Present (either modality) 4 
Imaging evidence of gout-related joint 
damage: 
conventional radiography of the hands 
and/or feet demonstrates at least 1 
erosion 
 
Present 4 
 
 
Entry criterion: At least 1 episode of swelling, pain, or tenderness in a peripheral joint or 
bursa. Sufficient criterion: Presence of MSU crystals in a symptomatic joint or bursa (i.e., in 
synovial fluid) or tophus. If Entry criteria met and sufficient criteria not met then can apply 
the above classification criteria. If the patient has a score ≥8 then they can be classified as 
having gout with a sensitivity of 92% and specificity of 89%.  
 
ACR: American College of Rheumatology; EULAR European League Against Rheumatism; 
DECT Dual energy computed tomography 
 
 
1. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 
Gout classification criteria: an American College of Rheumatology/European League Against 
Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-98. 
 
Table 3: American College of Rheumatology Guidelines Recommended Allopurinol Up-
titration regime(1) 
 
 GFR > 30mL/min GFR < 30mL/min 
Starting dose 100mg 50mg 
Up-titration dose 100mg 50mg 
Up-titration interval 2 - 5 weeks 2 - 5 weeks 
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1. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American 
College of Rheumatology guidelines for management of gout. Part 1: systematic 
nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis 
Care Res (Hoboken). 2012;64(10):1431-46. 
 
 
Table 4 American College of Rheumatology indications for commencing urate lowering 
therapy (1) 
 
1. CKD stage 2 or worse  
2. Tophus or tophi by clinical examination or imaging study 
3. Previous or current kidney stones 
4. More than 1 gout flare per year 
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Care Res (Hoboken). 2012;64(10):1431-46. 
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